Next Article in Journal
Thyroid Hormone T3 Induces DNA Damage Response in Breast Cancer Cells
Previous Article in Journal
From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection
Previous Article in Special Issue
The Need for a Systems Biology Approach in Cancer Explained
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 27
Issue 2
10.3390/ijms27020665
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Int. J. Mol. Sci. 2025, 26(21), 10777.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Nishikubo et al. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777

by
Hinano Nishikubo
1,
Dongheng Ma
1,
Tomoya Sano
1,
Daiki Imanishi
1,
Takashi Sakuma
1,
Canfeng Fan
1,
Yurie Yamamoto
1,
Motohiro Yamamori
2 and
Masakazu Yashiro
1,3,*
1
Molecular Oncology and Therapeutics, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
2
Department of Clinical Pharmacy, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women’s University, Nishinomiya 663-8179, Japan
3
Cancer Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2026, 27(2), 665; https://doi.org/10.3390/ijms27020665
Submission received: 9 December 2025 / Accepted: 12 December 2025 / Published: 9 January 2026
(This article belongs to the Special Issue 25th Anniversary of IJMS: Updates and Advances in Molecular Oncology)
Versions Notes
In the original publication [1], the Institutional Review Board Statement and Informed Consent Statement were not included. In addition, the authors modified the Abstract after identifying an error; the phrase “Among 515 FGFR2 alteration cases” to “Among 1312 FGFR2 alteration cases”. The correct Institutional Review Board Statement and Informed Consent Statement appear below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
  • Institutional Review Board Statement: This study was approved by the C-CAT review committee (C-CAT management number: CDU2022-044N on 29 November 2022) and by the medical ethics committee of Osaka Metropolitan University (approval number 2022-111 on 15 September 2022).
  • Informed Consent Statement: Informed consent was waived by the Medical Ethics Committee of Osaka Metropolitan University.

Reference

  1. Nishikubo, H.; Ma, D.; Sano, T.; Imanishi, D.; Sakuma, T.; Fan, C.; Yamamoto, Y.; Yamamori, M.; Yashiro, M. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Nishikubo, H.; Ma, D.; Sano, T.; Imanishi, D.; Sakuma, T.; Fan, C.; Yamamoto, Y.; Yamamori, M.; Yashiro, M. Correction: Nishikubo et al. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777. Int. J. Mol. Sci. 2026, 27, 665. https://doi.org/10.3390/ijms27020665

AMA Style

Nishikubo H, Ma D, Sano T, Imanishi D, Sakuma T, Fan C, Yamamoto Y, Yamamori M, Yashiro M. Correction: Nishikubo et al. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777. International Journal of Molecular Sciences. 2026; 27(2):665. https://doi.org/10.3390/ijms27020665

Chicago/Turabian Style

Nishikubo, Hinano, Dongheng Ma, Tomoya Sano, Daiki Imanishi, Takashi Sakuma, Canfeng Fan, Yurie Yamamoto, Motohiro Yamamori, and Masakazu Yashiro. 2026. "Correction: Nishikubo et al. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777" International Journal of Molecular Sciences 27, no. 2: 665. https://doi.org/10.3390/ijms27020665

APA Style

Nishikubo, H., Ma, D., Sano, T., Imanishi, D., Sakuma, T., Fan, C., Yamamoto, Y., Yamamori, M., & Yashiro, M. (2026). Correction: Nishikubo et al. FGFR2 Might Be a Promising Therapeutic Target for Some Solid Tumors: Analysis of 1312 Cancers with FGFR2 Abnormalities. Int. J. Mol. Sci. 2025, 26, 10777. International Journal of Molecular Sciences, 27(2), 665. https://doi.org/10.3390/ijms27020665

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop